Cargando…
The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
Enzalutamide is a second-generation anti-androgen which has shown increased survival in patients with metastatic prostate cancer. However, some patients do not respond to this therapy or will develop resistance to treatment over time. Signal Transducer and Activator of Transcription 3 (STAT3) is kno...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344336/ https://www.ncbi.nlm.nih.gov/pubmed/35917644 http://dx.doi.org/10.1016/j.tranon.2022.101495 |